创新药ETF国泰（517110）涨超1.4%，政策支持与行业回暖提振市场信心

Group 1 - The core viewpoint of the article highlights the positive impact of recent healthcare policy initiatives on the innovation drug and medical device sectors in China, particularly through the support of the National Healthcare Security Administration [1] - The National Healthcare Security Administration has held two meetings to discuss new measures for supporting innovative drugs and medical devices, including the introduction of a unified pricing mechanism for new medical services and encouraging differentiated innovation [1] - The article notes that since the implementation of the new regulatory measures for high-end medical devices in June 2025, there has been a clear shift towards supporting genuine innovation in the healthcare sector, which is expected to enhance the profitability and valuation levels of the medical device sector [1] Group 2 - The article mentions that the Guotai Innovation Drug ETF (517110) has risen over 1.4%, reflecting the positive sentiment in the market towards innovative drug companies [1] - The SHS Innovation Drug Index (931409), which the Guotai Innovation Drug ETF tracks, includes companies involved in the research and production of innovative drugs, covering sectors such as biomedicine and chemical pharmaceuticals [1] - The index constituents are characterized by significant growth potential and research investment, indicating a growth-oriented investment style [1]